Selected Grants
Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligometastatic Non-Small Cell Lung Cancer and Rena
Clinical TrialPrincipal Investigator · Awarded by ImmuneSensor Therapeutics, Inc. · 2024 - 2024External Relationships
- Duke Cancer Network
- Telix Pharmaceuticals Limited
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.